Financial Architects, Inc Mirati Therapeutics, Inc. Transaction History

Financial Architects, Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 01, 2019	SELL	$32.0 - $47.43 $3,200 - $4,743	-100 Closed	0 $0
Q3 2018 Oct 29, 2018	BUY	$47.1 - $62.7 $4,710 - $6,270	100 New	100 $5,000
Q2 2018 Aug 03, 2018	SELL	$26.05 - $52.4 $36,470 - $73,360	-1,400 Closed	0 $0
Q1 2018 Apr 23, 2018	BUY	$17.2 - $34.95 $6,020 - $12,232	350 Added 33.33%	1,400 $43,000
Q3 2017 Nov 01, 2017	BUY	$4.7 - $11.7 $4,935 - $12,285	1,050	1,050 $12,000

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Financial Architects, Inc, based on Form 13F filings with the SEC.

Stay updated on Financial Architects, Inc with notifications on news.